A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
000A18_MPR_0210.qxp 1/27/2010 3:20 PM Page 1 NEWSLINE Highlights of recent developments Sumavel DosePro available H1N1 vaccine monitoring Bacitracin Oph. Ointment The FDA has issued a letter to update healthcare profes- sionals on the FDA/CDC experience with the H1N1 vaccination program and to provide details on the cur- rent vaccine safety monitor- ing program. The FDA and CDC are assessing H1N1 vaccine safety on a continu- Zogenix and Astellas have ing basis and have published Fera has made Bacitracin made available Sumavel a report describing the safety ophthalmic ointment readily DosePro (sumatriptan profile of H1N1 vaccines in available again. Previously, injection), a selective the U.S. No substantial dif- only a limited quantity 5-HT1B/1D receptor agonist ferences between H1N1 and of this prescription anti- in a needle-free delivery seasonal influenza vaccines infective ophthalmic had system, for the acute treat- were noted in the propor- been available. Bacitracin ment of migraine attacks, tion or types of serious ophthalmic ointment is indi- with or without aura, and adverse events reported. cated to treat susceptible the acute treatment of No increase in any of the superficial ocular infections cluster headache episodes. preselected adverse events involving the conjunctiva Sumavel DosePro is avail- under surveillance (eg, and/or cornea. able as a 6mg/0.5mL single- Guillain-Barré syndrome) For more information use, disposable injection. has been seen in Vaccine call (414) 434-6604. For more information Safety Datalink data. call (866) ZOGENIX. For more information visit Spiriva HandiHaler update www.fda.gov/NewsEvents/ The FDA announced that Adrenaclick Auto-injector PublicHealthFocus/ucm197 data from a recent review of Sciele Pharma announced 733.htm. Spiriva HandiHaler (tiotro- that Adrenaclick (epineph- pium dry powder for inhala- rine auto-injector) is avail- Sulfite-free sfRowasa tion, from Boehringer able for the treatment of sfRowasa (mesalamine Ingelheim) do not support severe allergic reactions rectal suspension), a sulfite- an increased risk of stroke, (Type I). These reactions free formulation of Rowasa heart attack, or death. This include anaphylaxis to sting- has been made available to communication is based on a ing and biting insects, aller- treat active mild to moder- review of the Understanding gen immunotherapy, foods, ate di
Pages to are hidden for
"NEWSLINE"Please download to view full document